rts logo

Which institution holds the most shares in Intellia Therapeutics Inc (NTLA)

Intellia Therapeutics Inc (NASDAQ: NTLA) is -18.07% lower on its value in year-to-date trading and has touched a low of $22.67 and a high of $47.48 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NTLA stock was last observed hovering at around $25.10 in the last trading session, with the day’s loss setting it -0.12%.

Currently trading at $24.98, the stock is -10.67% and -9.55% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.16 million and changing -0.48% at the moment leaves the stock -22.74% off its SMA200. NTLA registered -32.98% loss for a year compared to 6-month gain of -15.06%. The firm has a 50-day simple moving average (SMA 50) of $44.45 and a 200-day simple moving average (SMA200) of -$3.18.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The stock witnessed a -22.88% loss in the last 1 month and extending the period to 3 months gives it a -18.95%, and is -4.87% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.98% over the week and 5.05% over the month.

Intellia Therapeutics Inc (NTLA) has around 526 employees, a market worth around $2.40B and $36.27M in sales. Profit margin for the company is -1326.51%. Distance from 52-week low is 10.21% and -47.39% from its 52-week high. The company has generated returns on investments over the last 12 months (-41.96%).

Intellia Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$1.38 with sales reaching $11.5M over the same period.The EPS is expected to shrink by -2.56% this year, but quarterly earnings will post 39.80% year-over-year.

424 institutions hold shares in Intellia Therapeutics Inc (NTLA), with institutional investors hold 88.52% of the company’s shares. The shares outstanding are 96.11M, and float is at 93.89M with Short Float at 14.38%. Institutions hold 87.34% of the Float.

The top institutional shareholder in the company is ARK Investment Management, LLC with over 9.95 million shares valued at $314.58 million. The investor’s holdings represent 11.24% of the NTLA Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 8.19 million shares valued at $333.79 million to account for 9.25% of the shares outstanding. The other top investors are Blackrock Inc. which holds 8.05 million shares representing 9.10% and valued at over $328.48 million, while State Street Corporation holds 3.95% of the shares totaling 3.49 million with a market value of $142.44 million.

Intellia Therapeutics Inc (NTLA) Insider Activity

The most recent transaction is an insider sale by BASTA JAMES, the company’s EVP, General Counsel. SEC filings show that BASTA JAMES sold 2,297 shares of the company’s common stock on Mar 04 ’24 at a price of $32.99 per share for a total of $75778.0. Following the sale, the insider now owns 81571.0 shares.

Intellia Therapeutics Inc disclosed in a document filed with the SEC on Mar 04 ’24 that Clark Eliana (EVP, Chief Technical Officer) sold a total of 605 shares of the company’s common stock. The trade occurred on Mar 04 ’24 and was made at $32.99 per share for $19959.0. Following the transaction, the insider now directly holds 71470.0 shares of the NTLA stock.

Still, SEC filings show that on Jan 08 ’24, Sepp-Lorenzino Laura (EVP, Chief Scientific Officer) disposed off 2,275 shares at an average price of $28.87 for $65682.0. The insider now directly holds 43,927 shares of Intellia Therapeutics Inc (NTLA).

Related Posts